Compare EYE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYE | LBRX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2017 | 2025 |
| Metric | EYE | LBRX |
|---|---|---|
| Price | $18.76 | $42.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $27.00 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 2.1M | 318.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | 98.22 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,987,488,000.00 | N/A |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $23.32 | ★ N/A |
| Revenue Growth | ★ 9.00 | N/A |
| 52 Week Low | $14.75 | $15.19 |
| 52 Week High | $30.02 | $50.16 |
| Indicator | EYE | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 56.82 |
| Support Level | $15.52 | $37.99 |
| Resistance Level | $20.98 | $49.74 |
| Average True Range (ATR) | 1.13 | 2.53 |
| MACD | 0.11 | 0.36 |
| Stochastic Oscillator | 84.35 | 63.95 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.